Developer docs
API playgroundTry for free, no card

Search company profiles

Somahlution

Full company profile

uuid000oufo

Namestring
Somahlution
Legal namestring
Marizyme Inc
Websiteurl
somahlution.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Marizyme Inc is a privately held medical technology company headquartered at 1645 Palm Beach Lakes Blvd, Suite 1200, West Palm Beach, Florida. The firm develops and commercializes a single product, DuraGraft, which is the first and only FDA-cleared solution indicated for the flushing and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG) surgery. The company serves hospitals and cardiovascular surgery centers performing CABG procedures, where harvested saphenous veins are vulnerable to oxidative damage during the intraoperative period between harvest and implantation. The firm was founded in 2010 and operates with a headcount of 1–10 employees, consistent with a focused single-product specialty medical device company.

DuraGraft is a vascular graft protection solution designed to be applied to saphenous vein grafts ex vivo to reduce oxidative damage during intraoperative storage, maintain endothelial cell viability, and preserve structural integrity of the conduit. Clinical evidence cited by the company indicates that saphenous vein grafts stored in DuraGraft exhibit significantly less wall thickening at 12 months post-CABG compared to grafts stored in saline, the historical standard. The technology operates as a single-use intraoperative consumable used at the point of care by cardiac surgical teams, and is regulated as an FDA-cleared medical device under 21 CFR Part 820 quality regulations.

The revenue model is not publicly disclosed, and the source materials do not specify pricing, distribution channels, or unit volumes. Given the single-product, hospital-channel profile of the business, monetization most likely occurs through unit sales of DuraGraft consumables to cardiovascular surgery departments via standard medical device distribution channels. No information on distributor agreements, GPO contracts, sales force composition, or capital structure is available in the source data, leaving commercial mechanics largely opaque.

Short descriptiontext

Marizyme Inc is a medical technology company that develops and markets DuraGraft, the first and only FDA-cleared solution for flushing and storage of saphenous vein grafts during coronary artery bypass grafting (CABG) surgery, serving hospitals and cardiovascular surgery centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersJupiter, United States
HQ citystring
Jupiter
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vascular graft protection, cardiac surgery devices, CABG graft storage, medical device solutions, vein graft preservation
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Vascular Surgery Medical Devices
Social media profiles2 records
Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1DuraGraft
Description

The First and Only FDA-cleared solution for the flushing and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG). Designed to help reduce oxidative damage during intraoperative storage, and to maintain cell viability and structural integrity.

marizyme.com
Core offering1 text field

Somahlution develops and markets DuraGraft, an FDA-cleared medical technology solution used during Coronary Artery Bypass Grafting (CABG) surgery for the flushing and storage of saphenous vein grafts. The product is designed to reduce oxidative damage during intraoperative storage and to maintain cell viability and structural integrity of the graft prior to transplantation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Saphenous vein grafts stored in DuraGraft exhibited significantly less wall thickening at 12 months post-CABG compared to those stored in saline.
Product overview1 text field

Marizyme Inc offers a single unified medical technology product: DuraGraft. DuraGraft is an FDA-cleared vascular graft protection solution specifically designed for use during Coronary Artery Bypass Grafting (CABG) surgery. The technology focuses on protecting the structural integrity of harvested saphenous vein grafts during the intraoperative storage period.

Product and service1 record
1DuraGraft
CategoryVascular graft protection / cardiac surgery consumable
Description

DuraGraft is an FDA-cleared vascular graft protection solution used during Coronary Artery Bypass Grafting (CABG) surgery for the flushing and storage of saphenous vein grafts. It is designed to reduce oxidative damage during intraoperative storage and to maintain cell viability and structural integrity. It is intended for use by cardiac surgery teams in hospitals and cardiovascular surgery centers.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specializes in organ, tissue, and cell preservation solutions (e.g., Celsior, Custodiol) used in transplant and cardiac surgery, the same clinical problem space as DuraGraft — protecting harvested biological tissue from ischemic and oxidative damage. Highly comparable mechanism and customer set (cardiac surgery centers).

TypeBroad incumbent
Description

Major cardiovascular surgery company offering heart-lung machines, oxygenators, and cardioplegia solutions used in CABG. Comparable end customer (cardiac surgery teams, perfusionists) and adjacency through intraoperative solutions used during CABG procedures.

TypeBroad incumbent
Description

Provides cardiovascular surgery equipment, perfusion disposables, and operating-room solutions used in CABG workflows. Comparable through shared perfusion/cabg customer base and OR-channel access, with broad portfolio rather than a single niche product.

TypeBroad incumbent
Description

Largest cardiovascular device company with broad CABG and interventional cardiology portfolios. Comparable as a large incumbent serving cardiac surgeons and perfusionists with overlapping workflow touchpoints, though no direct DuraGraft-equivalent product.

TypeBroad incumbent
Description

Broad cardiovascular portfolio spanning interventional and surgical heart disease products. Comparable as a scaled incumbent serving cardiac surgery centers, with the channel and resources to enter graft protection if commercially attractive.

TypeDirect peer
Description

Develops, manufactures, and commercializes products for cardiac and vascular surgery including tissue preservation, BioGlue surgical adhesive, and On-X mechanical heart valves. Directly comparable as a cardiac-surgery-focused company with tissue/graft protection offerings and overlap in CABG-adjacent customers.

TypeBroad incumbent
Description

Cardiac surgery and structural heart leader with surgical tissue heart valves and critical care monitoring used in CABG. Comparable through shared cardiac surgery customers and operating-room channel, though focused on valves rather than graft protection.

TypeDirect peer
Description

Specialist in organ and tissue preservation, including machine perfusion and storage solutions for transplant and cardiac applications. Closely comparable niche focus on protecting harvested biological tissue — directly analogous technology and clinical use case to DuraGraft.

TypeBroad incumbent
Description

Surgical solutions business includes products used in operating rooms and cardiac surgery (e.g., infusion systems, surgical sealants). Comparable through overlapping OR and perfusion customers and through incumbency in surgical fluids and adjunctive products.

10Terumo Cardiovascular
TypeBroad incumbent
Description

Global supplier of cardiovascular surgery products including perfusion systems, oxygenators, and surgical instruments for CABG. Operates in the same surgical workflow and customer base as DuraGraft, with broader portfolio reach into the operating room.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Somahlution

Vascular Surgery Medical Devicessomahlution.com

Marizyme Inc is a medical technology company that develops and markets DuraGraft, the first and only FDA-cleared solution for flushing and storage of saphenous vein grafts during coronary artery bypass grafting (CABG) surgery, serving hospitals and cardiovascular surgery centers.

What Somahlution does

Marizyme Inc is a privately held medical technology company headquartered at 1645 Palm Beach Lakes Blvd, Suite 1200, West Palm Beach, Florida. The firm develops and commercializes a single product, DuraGraft, which is the first and only FDA-cleared solution indicated for the flushing and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG) surgery. The company serves hospitals and cardiovascular surgery centers performing CABG procedures, where harvested saphenous veins are vulnerable to oxidative damage during the intraoperative period between harvest and implantation. The firm was founded in 2010 and operates with a headcount of 1–10 employees, consistent with a focused single-product specialty medical device company.

DuraGraft is a vascular graft protection solution designed to be applied to saphenous vein grafts ex vivo to reduce oxidative damage during intraoperative storage, maintain endothelial cell viability, and preserve structural integrity of the conduit. Clinical evidence cited by the company indicates that saphenous vein grafts stored in DuraGraft exhibit significantly less wall thickening at 12 months post-CABG compared to grafts stored in saline, the historical standard. The technology operates as a single-use intraoperative consumable used at the point of care by cardiac surgical teams, and is regulated as an FDA-cleared medical device under 21 CFR Part 820 quality regulations.

The revenue model is not publicly disclosed, and the source materials do not specify pricing, distribution channels, or unit volumes. Given the single-product, hospital-channel profile of the business, monetization most likely occurs through unit sales of DuraGraft consumables to cardiovascular surgery departments via standard medical device distribution channels. No information on distributor agreements, GPO contracts, sales force composition, or capital structure is available in the source data, leaving commercial mechanics largely opaque.

Somahlution firmographics

Firmographics
Name
Somahlution
Legal name
Marizyme Inc
Website
https://somahlution.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Marizyme Inc is a medical technology company that develops and markets DuraGraft, the first and only FDA-cleared solution for flushing and storage of saphenous vein grafts during coronary artery bypass grafting (CABG) surgery, serving hospitals and cardiovascular surgery centers.
Ownership category
akta.pro rank

Somahlution industry classification

Industry
Product category
Vascular Surgery Medical Devices
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Vascular graft protection
  • Cardiac surgery devices
  • CABG graft storage
  • Medical device solutions
  • Vein graft preservation

Where Somahlution is headquartered

Location

Headquarters

HQ city
Jupiter
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Somahlution business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Somahlution product offering

Product offering

Core offering

Somahlution develops and markets DuraGraft, an FDA-cleared medical technology solution used during Coronary Artery Bypass Grafting (CABG) surgery for the flushing and storage of saphenous vein grafts. The product is designed to reduce oxidative damage during intraoperative storage and to maintain cell viability and structural integrity of the graft prior to transplantation.

Product overview

Marizyme Inc offers a single unified medical technology product: DuraGraft. DuraGraft is an FDA-cleared vascular graft protection solution specifically designed for use during Coronary Artery Bypass Grafting (CABG) surgery. The technology focuses on protecting the structural integrity of harvested saphenous vein grafts during the intraoperative storage period.

Differentiator

Problem solved

Functional benefit

Brands

  • DuraGraft: The First and Only FDA-cleared solution for the flushing and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG). Designed to help reduce oxidative damage during intraoperative storage, and to maintain cell viability and structural integrity.

Products and services

  • DuraGraft DuraGraft is an FDA-cleared vascular graft protection solution used during Coronary Artery Bypass Grafting (CABG) surgery for the flushing and storage of saphenous vein grafts. It is designed to reduce oxidative damage during intraoperative storage and to maintain cell viability and structural integrity. It is intended for use by cardiac surgery teams in hospitals and cardiovascular surgery centers.

Quantifiable outcome

  • Saphenous vein grafts stored in DuraGraft exhibited significantly less wall thickening at 12 months post-CABG compared to those stored in saline.

Companies that use Somahlution

Customer profile

Segments1 record

Ideal customer profiles1 record

Somahlution technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Somahlution partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Somahlution competitors and assessment

Company assessment

Direct peers

  • Adienne Pharma & Biotech: Specializes in organ, tissue, and cell preservation solutions (e.g., Celsior, Custodiol) used in transplant and cardiac surgery, the same clinical problem space as DuraGraft — protecting harvested biological tissue from ischemic and oxidative damage. Highly comparable mechanism and customer set (cardiac surgery centers).
  • Artivion (formerly CryoLife): Develops, manufactures, and commercializes products for cardiac and vascular surgery including tissue preservation, BioGlue surgical adhesive, and On-X mechanical heart valves. Directly comparable as a cardiac-surgery-focused company with tissue/graft protection offerings and overlap in CABG-adjacent customers.
  • XVIVO Perfusion: Specialist in organ and tissue preservation, including machine perfusion and storage solutions for transplant and cardiac applications. Closely comparable niche focus on protecting harvested biological tissue — directly analogous technology and clinical use case to DuraGraft.

Broad incumbents

  • LivaNova: Major cardiovascular surgery company offering heart-lung machines, oxygenators, and cardioplegia solutions used in CABG. Comparable end customer (cardiac surgery teams, perfusionists) and adjacency through intraoperative solutions used during CABG procedures.
  • Getinge (Cardiovascular): Provides cardiovascular surgery equipment, perfusion disposables, and operating-room solutions used in CABG workflows. Comparable through shared perfusion/cabg customer base and OR-channel access, with broad portfolio rather than a single niche product.
  • Medtronic: Largest cardiovascular device company with broad CABG and interventional cardiology portfolios. Comparable as a large incumbent serving cardiac surgeons and perfusionists with overlapping workflow touchpoints, though no direct DuraGraft-equivalent product.
  • Abbott Cardiovascular: Broad cardiovascular portfolio spanning interventional and surgical heart disease products. Comparable as a scaled incumbent serving cardiac surgery centers, with the channel and resources to enter graft protection if commercially attractive.
  • Edwards Lifesciences: Cardiac surgery and structural heart leader with surgical tissue heart valves and critical care monitoring used in CABG. Comparable through shared cardiac surgery customers and operating-room channel, though focused on valves rather than graft protection.
  • Baxter International: Surgical solutions business includes products used in operating rooms and cardiac surgery (e.g., infusion systems, surgical sealants). Comparable through overlapping OR and perfusion customers and through incumbency in surgical fluids and adjunctive products.
  • Terumo Cardiovascular: Global supplier of cardiovascular surgery products including perfusion systems, oxygenators, and surgical instruments for CABG. Operates in the same surgical workflow and customer base as DuraGraft, with broader portfolio reach into the operating room.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights4 records

Customer concentration

Somahlution social profiles

Digital presence

Somahlution compliance and trust

Trust signal

Compliance1 record

Somahlution financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Somahlution leadership team

Management profile

Number of profiles

Somahlution funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Somahlution M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Somahlution

What does Somahlution do?

Somahlution develops and markets DuraGraft, an FDA-cleared medical technology solution used during Coronary Artery Bypass Grafting (CABG) surgery for the flushing and storage of saphenous vein grafts. The product is designed to reduce oxidative damage during intraoperative storage and to maintain cell viability and structural integrity of the graft prior to transplantation.

Is Somahlution a public or private company?

Somahlution is a private company. It is classified as unknown and is currently operating.

When was Somahlution founded?

Somahlution was founded in 2010. It employs 1 to 10 people.

Where is Somahlution based?

Somahlution is headquartered in Jupiter, United States, in the North America region.

Who are Somahlution's main competitors?

Direct peers on record are Adienne Pharma & Biotech, Artivion (formerly CryoLife) and XVIVO Perfusion. Broad incumbents are LivaNova, Getinge (Cardiovascular), Medtronic, Abbott Cardiovascular, Edwards Lifesciences, Baxter International and Terumo Cardiovascular.

Does Somahlution have an API?

No public API is recorded for Somahlution.

What industry is Somahlution in?

Somahlution's product category is Vascular Surgery Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals